Well Referenced

Tag: mCRPC

Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

This 2021 commentary by Hadaschik and Herrmann discusses the findings of the VISION trial, which evaluated the efficacy of Lutetium-177-PSMA-617 (Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC). The VISION trial demonstrated that Lu-PSMA-617, when added to standard care, significantly improved both imaging-based progression-free survival (8.7 vs. 3.4 months)

Read More »
June 26, 2025 No Comments

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

This 2013 phase II trial evaluated the antifungal drug itraconazole as a potential therapy for chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). Forty-six patients were randomized to receive either low-dose (200 mg/day) or high-dose (600 mg/day) oral itraconazole. The primary endpoint was the 24-week prostate-specific antigen (PSA) progression-free survival

Read More »
June 26, 2025 No Comments